Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.
The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.
Sales in the life science segment grew 5 percent due in part to sales of the firm's Digital Droplet PCR system and reagents.
The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents.
The firm's topline performance for the full year was also higher than previous guidance provided by the company and analyst estimates.
A jury in Northern California has found that Sanford Wadler was wrongfully terminated and awarded him back pay and punitive damages.
Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.